- Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
- A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
CureVac shares were lower on Monday even as the German biopharma reported progress in animal testing of its coronavirus vaccine candidate. The company, which is developing an mRNA vaccine to combat covid, unveiled data showing "robust" antibody and T-cell responses to its vaccine candidate in rhesus macaques. "Full protection of the lungs of vaccinated animals supports CVnCoV's potential in protecting humans from the devastating effects the virus has," said Mariola Fotin-Mleczek, chief techno...
* Data provided further evidence on immunogenicity and protective efficacy of CVnCoV * Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial * Full lung protection of CVnCoV-vaccinated animals during SARS-CoV-2 challenge infection TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 11, 2021 / CureVac N. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today...
(Bloomberg Opinion) -- The night is darkest just before dawn, they say. Dark it certainly is right now. The more contagious variants of SARS-CoV-2 coming out of the U.K. and South Africa will make the pandemic worse before mass vaccination can make it better.But take another look at some of these new vaccines. And then contemplate the dawn to come — not just its first rays in the coming months but also the bright light of future years and decades. It looks increasingly plausible that the same we...
The highflying IPO market got off to a strong start Friday with shares of two biotechnology companies—Cullinan Management and Gracell Biotechnologies—making rousing debuts. Cullinan rose 42.43% in its first day of trading, while Gracell gained nearly 32%. The offerings continue the trend of ramped-up demand for biotechs.
The German government signed two preliminary deals with German biotech firms BioNTech and CureVac in the summer to secure 50 million doses of their COVID-19 vaccines, according to a health ministry document and an official. The deals, which were not announced when they were signed, are controversial because EU governments had agreed not to negotiate bilateral supply agreements with vaccine makers in a effort to avoid vying for shots. The ministry official, speaking on condition of anonymity, s...
CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.